News | News By Subject | News by Disease News By Date | Search News

ALS (Lou Gehrig's disease) News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Comeback Kid Cytokinetics (CYTK) Pockets $95 Million Upfront in R&D Deal With Astellas (ALPMY), Needs Results for More     7/27/2016
Iron Horse Therapeutics Launched By Avalon Ventures and GlaxoSmithKline (GSK)     11/10/2015
Biogen (BIIB), the ALS Association and Columbia University Medical Center to Map ALS With Ice Bucket Cash     8/18/2015
How Cytokinetics (CYTK) Will Be Getting Some of That Ice Bucket Challenge Cash     7/15/2015
FDA, Genervon and ALS Blogger Battle Over Clinical Trial Interpretation     4/22/2015
Biogen (BIIB) Drops Idec From Corporate Name, Expands Ambitions in Alzheimer's, ALS     3/24/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Despite Conflicting Data, Cytokinetics, Inc. (CYTK) Plans To Take ALS Drug Into Late Stage Study     10/21/2014
BrainStorm Cell Therapeutics Inc. Nabs FDA Fast-Track Status For ALS Stem Cell Therapy     10/8/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) Poaches Renowned Neurologist From Novartis AG (NVS) To Lead ALS Innovation Hub     8/27/2014
Bay Area's Cytokinetics, Inc. (CYTK) Plummets As ALS Drug Fails Phase 2B Study; Stock Down -64.67% At Market Close (April 25, 2014)     4/28/2014
BrainStorm Cell Therapeutics Inc. Says Stem Cells Helped 75-Year Old Patient With ALS And MG     1/7/2014
Neuraltus Pharmaceuticals, Inc. Seeks $30 Million for New Lou Gehrig's Disease Drug Trial     10/10/2013

News from Around the Web
One Gene Predicts Rapid ALS Progression 80 Percent of the Time, Methodist Neurological Institute Study     12/10/2012
Stem Cell Model Offers Clues to Cause of Inherited ALS, University of California, San Diego (UCSD) Study     6/22/2011
Ring Finger Length Linked to ALS, King's College London Study Suggests     5/10/2011
Vitamin E Users Show Lower ALS Risk, Harvard University Study     3/17/2011
Cigarette Smoking May Increase Risk of Muscle-Wasting Disease, Harvard School of Public Health Study     2/15/2011
Blue-green Algae Tested for Treating ALS, University of South Florida Study     12/22/2010
Genetic Variations Linked to ALS Risk, University Of Montreal Study     8/31/2010
Brain Trauma Can Mimic Lou Gehrig's Disease, Veterans Affairs Medical Center and Boston University School of Medicine Study     8/18/2010
Cleveland Clinic Researcher Finds Treatment Eases Involuntary Laughing, Crying Tied to Alzheimer's, MS     4/16/2010
Lithium Shows No Benefit in ALS, Massachusetts General Hospital Study     4/6/2010
Compound Shows Potential For Slowing Progression Of Lou Gehrig's Disease, University of Rochester Medical Center Study     10/20/2009
Novel Human Stem Cell-based Model Of Amyotrophic Lateral Sclerosis Opens Doors For Rapid Drug Screening, Salk Institute for Biological Studies Study     12/5/2008
Neurons Derived From Embryonic Stem Cells Restore Muscle Function After Injury, Dalhousie University Study     11/21/2008
University of Rochester Gene Find Sheds Light On Motor Neuron Diseases Like ALS     10/27/2008
Statins Don't Increase "Lou Gehrig's" Risk, FDA Reports     9/30/2008

Press Releases
Towards The Company's First Clinical Trial; Kadimastem Signs Letter Of Intent With Hadassah Medical Center For Performance Of The Clinical Trial In ALS     11/3/2016
PatientsLikeMe Launches Virtual Trial For ALS Patients     10/25/2016
Cytokinetics (CYTK) Announces First Patient Enrolled In VIGOR-ALS, An Open-Label Extension Clinical Trial Of Tirasemtiv     10/18/2016
Synapse Biomedical Release: New ALS Device Trial; The PARADIGM Study Will Continue Research Of The NeuRx Diaphragm Pacing System (DPS) In ALS Patients     10/4/2016
AB Science (AB.PA) Announces The Filing Of Masitinib In The Treatment Of Amyotrophic Lateral Sclerosis (ALS) To The EMA     9/30/2016
FDA Accepts Mitsubishi Tanabe's NDA Filing For Edaravone To Treat ALS     8/30/2016
Amylyx Announces $5 Million Series A Financing To Support Phase II Clinical Trial Of AMX0035 For Treatment Of Amyotrophic Lateral Sclerosis     8/22/2016
Cytokinetics (CYTK) Completes Enrollment In VITALITY-ALS, Phase III Clinical Trial Of Tirasemtiv In Patients With ALS     8/17/2016
The ALS Association Release: New Protein Target Emerges For C9orf72 The Most Common Genetic Form Of ALS     8/12/2016
The ALS Association And ALS Finding A Cure Announce Joint Funding Support For Amylyx Clinical Trial Of AMX0035 For The Treatment Of ALS     7/20/2016
Mitsubishi Tanabe Submits New Drug Application For Edaravone To Treat ALS In The United States     6/20/2016
NeuralStem Inc. To Raise $1.08 Million     5/13/2016
BrainStorm Cell Reports First Quarter 2016 Financial Results And Provides Corporate Update     5/10/2016
RXi Pharma (RXII) And Thera Neuropharma Enter Into An Exclusive License Agreement For RXi's Self-Delivering RNAi (sd-rxRNA) Platform Targeting SOD1 To Develop Therapeutics For Neurodegenerative Diseases, Such As ALS (Lou Gehrig's Disease)     5/3/2016
Biomarker Analyses Of Neuraltus Pharmaceuticals, Inc.' NP001 Phase 2 Data Demonstrate Potential For Treating ALS Patients With Systemic Inflammation     4/4/2016

//-->